Treatment of Vaginal Lichen Sclerosus with Clobetasol Propionate Cream

Initial Treatment Regimen

The British Journal of Dermatology recommends clobetasol propionate 0.05% cream as the first-line treatment for lichen sclerosus affecting the vaginal area, applied once daily at night for 4 weeks, then on alternate nights for 4 weeks, and finally twice weekly for 4 weeks before reassessment 1, 2, 3
A 30g tube of clobetasol propionate 0.05% cream should last approximately 12 weeks when used as directed, according to the British Journal of Dermatology 1, 2

After the initial 12-week treatment period, patients should be assessed for response, as recommended by the British Journal of Dermatology 1
About 60% of patients will experience complete remission of symptoms, according to the British Journal of Dermatology 1, 4
For patients with ongoing disease, the British Journal of Dermatology recommends continuing clobetasol propionate 0.05% as needed for flares 1, 3
Most patients with ongoing disease require 30-60g of clobetasol propionate 0.05% annually, as reported by the British Journal of Dermatology 1, 4

Apply a thin layer of clobetasol propionate 0.05% cream to affected areas only, as advised by Praxis Medical Insights 5
Use a soap substitute in the affected area to prevent irritation, as recommended by Praxis Medical Insights 5
Advise patients on thorough hand-washing after application to avoid spreading medication to sensitive areas and to prevent partner exposure, according to The Journal of Urology 6

Long-term use of clobetasol propionate as described is safe with no evidence of significant steroid damage or increased risk of squamous cell carcinoma, as reported by the British Journal of Dermatology 1, 4

Mometasone furoate 0.1% has also shown effectiveness and may be considered as an alternative to clobetasol propionate 0.05% cream, according to the British Journal of Dermatology 1

Common local adverse effects of clobetasol propionate 0.05% cream include skin atrophy, striae, folliculitis, telangiectasia, and purpura, as reported by Praxis Medical Insights 5
Regular follow-up is recommended to assess treatment response and monitor for adverse effects, as advised by the British Journal of Dermatology 1, 2

If symptoms recur when reducing application frequency, patients should increase frequency until symptoms resolve, then attempt to reduce again, as recommended by the British Journal of Dermatology 1, 3
Successful treatment will resolve hyperkeratosis, ecchymoses, fissuring, and erosions, but atrophy, scarring, and pallor will persist, according to the British Journal of Dermatology 1, 3
Topical testosterone is not recommended as there is no evidence base for its use in lichen sclerosus, as stated by the British Journal of Dermatology 1, 4